CureVac N.V. (CVAC)
| Market Cap | 521.65M |
| Revenue (ttm) | 59.73M |
| Net Income (ttm) | -289.07M |
| Shares Out | 223.88M |
| EPS (ttm) | -1.26 |
| PE Ratio | n/a |
| Forward PE | 9.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 837,430 |
| Open | 2.320 |
| Previous Close | 2.310 |
| Day's Range | 2.280 - 2.420 |
| 52-Week Range | 2.215 - 12.360 |
| Beta | 2.51 |
| Analysts | Hold |
| Price Target | 6.00 (+157.51%) |
| Earnings Date | Apr 24, 2024 |
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncyti... [Read more]
Financial Performance
In 2023, CureVac's revenue was 53.76 million, a decrease of -20.26% compared to the previous year's 67.42 million. Losses were -260.17 million, 4.47% more than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CVAC stock is "Hold." The 12-month stock price forecast is $6.0, which is an increase of 157.51% from the latest price.
News
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA)...
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will...
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and stra...
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise Collaboration aims to develop novel, off-the-sh...
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended flu strains For influenza A strains, geometric mean titers numerically exceeded those elicited by...
CureVac stock gains as COVID vaccine candidates show promise
CureVac N.V. shares CVAC, +1.20% gained 3% premarket on Friday as the company released new data from a trial of its mRNA COVID-19 vaccine candidates, which it is developing in collaboration with GSK P...
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile Monovalent mRNA vaccine candidate, ...
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other ...
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine can...
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of...
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech Ruling on infringement to be provided latest once the validity...
CureVac signals progress on mRNA flu vaccine
CureVac NV CVAC, -3.85% said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results from an early-stage study conducted in collaborati...
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate Best-performing candidate providing broad...
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Initiated Ph...
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine deve...
Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology
NEW YORK--(BUSINESS WIRE)--Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically de...
CureVac Announces Update to the Management Team
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on m...
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in German...
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma Study designed to evaluate safety and immunogenici...
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 20, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on m...
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY and BOSTON, USA / ACCESSWIRE / June 19, 2023 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based ...
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Filed infringement...
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer t...
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S....